FDA
-
-
-
-
-
-
-
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
-
-
-
-
-
-
-
HOPE Therapeutics begins patient TMS treatments with Zeta navigation
-
-
-
-
-
-
-
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
-
-
-
-
-
-
-
NRX Pharmaceuticals begins commercial manufacturing for preservative-free ketamine
-
-
-
-
-
-
-
NRx Pharmaceuticals forms defense subsidiary for military therapy research
-
-
-
-
-
-
-
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application
-
-
-
-
-
-
-
NRx Pharmaceuticals meets with FDA on suicidal depression drug
-
331,504 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

